Telix Pharmaceuticals (TLX) began trading on the Nasdaq on Thur 14 Nov 24

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. 

• Sector: Healthcare
• Industry: Biotechnology
• Founded by Andreas Kluge and Christian P. Behrenbruch in 2015 
• Headquartered in Melbourne, Australia
• https://telixpharma.com

Globavend Holdings (GVH) : 6-month performance

Globavend Holdings Ltd. is an e-commerce logistics provider offering end-to-end logistics solutions in Hong Kong, Australia, and New Zealand. The company's customers are primarily enterprise customers, e-commerce merchants, or operators of e-commerce platforms that offer business-to-consumer (B2C) transactions. It offers a one-stop solution, from pre-carriage parcel drop-off to parcel consolidation, air-freight forwarding, customs clearance, on-carriage parcel transportation, and delivery. 

Globavend serves Hong Kong, as well as four cities in Australia and in New Zealand, and its customers are primarily business-to-consumer e-commerce merchants.

• Sector: Industrials
• Industry: Integrated Freight & Logistics
• Full Time Employees: 7
• Founded by Yau Wai Yiu in 2016 
• Headquartered in Perth, Australia
• https://globavend.com

IPO: November 8, 2023; raised $6 million by offering 1.5 million shares at $4, the low end of the range of $4 to $5. The company offered 0.4 million fewer shares than anticipated.

Benitec Biopharma (BNTC)

IPO: Aug. 18, 2015

Ticker: BNTC

 

Benitec Biopharma announces that the initial pre-clinical efficacy results of the OPMD program have been published in Nature Communications; studies demonstrate that a DNA directed RNA interference (ddRNAi) approach to 'silence and replace' the mutant PABPN1 protein:

• Co announces that the initial pre-clinical efficacy results of the OPMD program have been published in Nature Communications, an open access scientific journal published by the Nature Publishing Group. OPMD, a rare progressive muscle-wasting disease caused by mutation in the poly-binding protein nuclear 1 gene, is characterised by eyelid drooping, swallowing difficulties, and proximal limb weakness.
• The key results from these studies demonstrate that a DNA directed RNA interference approach to 'silence and replace' the mutant PABPN protein, results in the correction of the muscular dystrophy and of key clinical features of OPMD including a progressive atrophy and muscle weakness associated with nuclear aggregates of insoluble PABPN1. These data were generated in the A17 mouse model that expresses the mutant PABPN1 gene and mimics most of the features of human OPMD patients.

Description

Benitec Biopharma Limited is a biotechnology company. The Company is engaged in progressing programs through the clinic; the commercialization of its Intellectual Property (IP); development of its therapeutic pipeline and pre-clinical programs, and funding, and protecting and building the IP estate. Its In-house product candidates include TT-034, BB-HB-331, BB-AMD-211 and ddRNAi therapeutic. It is focused on commercialization by licensing and partnering of patents and licenses in biotechnology, in functional genomics, with applications in biomedical research and human therapeutics. It has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, deoxyribonucleic acid (DNA)-directed ribonucleic acid interference (ddRNAi). The Company is engaged in developing treatments for chronic human conditions, such as hepatitis B, wet age-related macular degeneration (AMD), and oculopharyngeal muscular dystrophy (OPMD) based on this technology.

Address

SE 1201 99 Mount St
NORTH SYDNEY, NSW 2060
Australia

Website 

 https://www.benitec.com